The Knight Cancer Institute at Portland-based Oregon Health & Science University has received a $2 billion gift from Phil and Penny Knight. The gift will be used to establish a new cancer care delivery model, enabling the institute to accelerate how quickly and effectively its cancer research discoveries are integrated into clinical care, according to an Aug. 14 news release from the university.

The university has established the Knight Cancer Group to govern the Knight Cancer Institute’s new model and manage OHSU’s cancer services. Brian Druker, MD, a professor of medicine in the division of hematology/medical oncology, the JELD-WEN chair of leukemia research and lead developer of the leukemia drug Gleevec, will serve as inaugural president of the organization.  “Penny and Phil Knight ha

See Full Page